➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Express Scripts
McKesson
Baxter
Mallinckrodt

Last Updated: October 16, 2021

DrugPatentWatch Database Preview

Sarilumab - Biologic Drug Details


Email this page to a colleague

« Back to Dashboard

Summary for sarilumab
Tradenames:1
Patents:18
Applicants:1
BLAs:1
Suppliers: see list1
Recent Clinical Trials: See clinical trials for sarilumab
Recent Clinical Trials for sarilumab

Identify potential brand extensions & biosimilar entrants

SponsorPhase
TCU and UNTHSC School of MedicinePhase 2
Fort Worth Clinical Sciences Working GroupPhase 2
University of Southern DenmarkPhase 1/Phase 2

See all sarilumab clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for sarilumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for sarilumab Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for sarilumab Derived from Patent Text Search

These patents were identified by searching patent claims

Supplementary Protection Certificates for sarilumab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2041177/01 Switzerland ⤷  Free Forever Trial PRODUCT NAME: SARILUMAB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66424 20.04.2018
2017000101 Germany ⤷  Free Forever Trial PRODUCT NAME: SARILUMAB; REGISTRATION NO/DATE: EU/1/17/1196 20170623
0911 Netherlands ⤷  Free Forever Trial PRODUCT NAME: SARILUMAB; REGISTRATION NO/DATE: EU/1/17/1196 20170627
C00050 Luxembourg ⤷  Free Forever Trial PRODUCT NAME: SARILUMAB ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (KEVZARA); AUTHORISATION NUMBER AND DATE: EU/1/17/1196 20170627
/2017 Austria ⤷  Free Forever Trial PRODUCT NAME: SARILUMAB; REGISTRATION NO/DATE: EU/1/17/1196 (MITTEILUNG) 20170627
01730049 Spain ⤷  Free Forever Trial PRODUCT NAME: SARILUMAB; NATIONAL AUTHORISATION NUMBER: EU/1/17/1196; DATE OF AUTHORISATION: 20170623; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1196; DATE OF FIRST AUTHORISATION IN EEA: 20170623
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Moodys
Baxter
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.